Home › Type 1 Diabetes › NCT06832410

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant

Who can join

Ages 18 to 65 · All sexes

Key Inclusion Criteria:

* Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
* Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
* Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study

Key Exclusion Criteria:

* Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks
* Participants had \>1 kidney transplant procedure

Other protocol defined Inclusion/Exclusion criteria may apply.

About the study

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

What is being tested

• Biological/Vaccine (biological)

Sponsor: Vertex Pharmaceuticals Incorporated · Participants: 10 · Started: Mar 31, 2025

Contact the study team

• Medical Information · Phone: 617-341-6777

Official record on ClinicalTrials.gov — NCT06832410

Locations in the U.S.

Conditions

• Type 1 Diabetes

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.